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Background: Bacterial constituents, such as Gram-negative
derived lipopolysaccharide (LPS), can initiate inflammatory
bone loss through induction of host-derived inflammatory cy-
tokines. The aim of this study was to establish a model of
aggressive inflammatory alveolar bone loss in rats using LPS
derived from the periodontal pathogen Actinobacillus actino-
mycetemcomitans.
Methods: Eighteen female Sprague-Dawley rats were divided
into LPS test (N = 12) and saline control (N = 6) groups. All an-
imals received injections to the palatal molar gingiva three
times per week for 8 weeks. At 8 weeks, linear and volumetric
alveolar bone loss was measured by micro-computed to-
mography (mCT). The prevalence of inflammatory infiltrate,
proinflammatory cytokines, and osteoclasts was assessed
from hematoxylin and eosin, immunohistochemical, or tartrate-
resistant acid phosphatase (TRAP)-stained sections. Statisti-
cal analysis was performed.
Results: A. actinomycetemcomitans LPS induced severe
bone loss over 8 weeks, whereas control groups were un-
changed. Linear and volumetric analysis of maxillae by mCT
indicated significant loss of bone with LPS administration. His-
tologic examination revealed increased inflammatory infil-
trate, significantly increased immunostaining for interleukin
IL-6 and -1b and tumor necrosis factor-alpha, and more
TRAP-positive osteoclasts in the LPS group compared to con-
trols.
Conclusion: Oral injections of LPS derived from the peri-
odontal pathogen A. actinomycetemcomitans can induce severe
alveolar bone loss and proinflammatory cytokine production
in rats by 8 weeks. J Periodontol 2007;78:550-558.
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P
eriodontitis is an oral infectious
disease that may result in tooth
loss. The hallmark of periodontitis
is bone resorption resulting from a host
inflammatory response to a bacterial
challenge. Periopathogenic bacteria, in-
cluding Actinobacillus actinomycetemco-
mitans, contain multiple virulence factors,
such as lipopolysaccharide (LPS), that
can activate the host inflammatory re-
sponse to initiate alveolar bone resorp-
tion.
LPS acts as a microbe-associated mo-
lecular pattern recognized through pat-
tern-recognition receptors on resident
immune and non-immune cells within
the periodontium.1 This immune re-
sponse involves recruitment of inflam-
matory cells, generation of prostanoids
and cytokines, elaboration of lytic en-
zymes, and osteoclast activation.2,3 Within
periodontal tissues and gingival crevicu-
lar fluid, activated monocytes, macro-
phages, and fibroblasts produce classic
proinflammatory cytokines, such as inter-
leukin (IL)-1b and -6 and tumor necrosis
factor-alpha (TNF-a).4-7 These cyto-
kines stimulate matrix metalloproteinases
(MMPs; e.g., the collagenases MMP-1, -3,
and -13), which destroy tissues through
degradation of extracellular matrix com-
ponents.Moreover, IL-1andTNF-a induce
bone resorption by indirectly stimulating
IL-6 or by directly stimulating downstream
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effectors associated with osteoclastogenesis, such as
receptor activator of nuclear factor-kappa B ligand
(RANKL). LPS itself can lead to increased osteoblastic
expression of prostaglandin E2, RANKL, IL-1, and
TNF-a.8 Additionally, in the presence of A. actinomy-
cetemcomitans, CD4+ T cells display an increased
expression of RANKL, thereby amplifying osteoclast
activation.9,10
Activation of the host immune response leads to
destruction of the periodontium via cytokine induc-
tion. Routinely, IL-1 and -6 and TNF-a are elevated
significantly in active versus inactive or healthy
sites.11-15 Also, IL-1 levels have been correlated pos-
itively to increased probing depth and clinical attach-
ment loss.12,14,16
Small animal models are used commonly in peri-
odontitis studies. In rats, a variety of approaches have
been used to create periodontitis, including ligature
placement, a soft diet, whole bacteria injection or bac-
terial oral gavage, and localized LPS injection.17-22 Al-
though all of these approaches generate inflammation
and alveolar bone loss, localized LPS injection may be
a more direct and controlled method, because a known
amount of inflammatory stimulus is delivered in a ti-
tratable manner.23 However, most studies using the
injection model isolated LPS from non-periopathogenic
bacteria, such as Escherichia coli or Salmonella typhi-
murium.23-25 The use of A. actinomycetemcomitans
LPS, as opposed to E. coli or S. typhimurium LPS,
is more relevant to periodontal disease. Recent studies
showed that A. actinomycetemcomitans can induce in-
flammatory bone loss in mice.26,27 A. actinomycetem-
comitans has been linked to aggressive periodontitis
(AP); itwas found inAP lesions,28 APpatientsexhibited
elevated serum antibodies to A. actinomycetemcomi-
tans,29 and reduction of A. actinomycetemcomitans
improved the clinical response of AP patients.30 In par-
ticular, serotype b is implicated most often.31,32 There-
fore, to establish an aggressive periodontitis model, we
selected A. actinomycetemcomitans serotype b (strain
Y4). In fact, the serotype determinants of A. actinomy-
cetemcomitans Y4 are associated with a high molec-
ular weight LPS-associated antigen.33 Accordingly,
in early-onset periodontitis patients with the highest
serum antibody levels to A. actinomycetemcomitans,
the predominant antibody specificity is to LPS.34,35
The purpose of this study was to develop a new
model for the induction of inflammatory alveolar bone




LPS was extracted from A. actinomycetemcomitans
strain Y4 (serotype B) by the hot phenol-water
method as described previously.36-38 The bacteria
were treated sequentially with lysozyme, DNAse,
RNAse, and proteases to extract and isolate the
LPS. The LPS used in the present study contained
<0.001% nucleic acid by spectrophotometry and
;0.7% protein by bicinchoninic acid protein assay.
The paucity of protein in the LPS preparations was
verified by polyacrylamide gel electrophoresis and
subsequent staining with silver nitrate and Coomassie
blue (Fig. 1). Gas chromatography/mass spectrome-
try of the fatty acids present in the A. actinomycetem-
comitans LPS preparations was performed. All peaks
present in the preparation after transmethylation were
identified by analysis of the mass spectral patterns as
described previously.39
Figure 1.
Characterization of A. actinomycetemcomitans LPS used in these
studies. A) Purified A. actinomycetemcomitans LPS demonstrated
characteristic laddering on a silver nitrate–stained polyacrylamide
gel with indicated quantities of A. actinomycetemcomitans LPS. B)
Absence of protein as indicated by Coomassie-stained gel with the
same LPS. C) Matrix-assisted laser desorption/ionization-time of flight
(MALDI-TOF) mass spectra showing singly charged anions representing
the major lipid A structures present. The major peak corresponds to the
hexa-acylated form (mass-to-charge ratio [m/z] at 1,827) with minor
forms being present as well.
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Animals
Based on data from previous studies us-
ing experimental periodontal disease
models,40,41 the estimated minimal
sample size for detecting a difference
of 50% between two groups is six ani-
mals per group. This was calculated
considering a power of 80%, P value of
0.05, normal distribution, and equiva-
lent variances of the experimental and
control groups.
Female adult Sprague-Dawley rats¶
(;250 g each) were housed in pairs un-
der specific pathogen-free conditions
with food and tap water ad libitum.
Once weekly, animals were weighed to
ensure proper growth and nutrition.
Injections were given three times
each week for 8 weeks. First, anesthesia
was induced with 4% to 5% isoflurane
and maintained with 1% to 2% isoflu-
rane. All rats received 2 ml total volume
of solution via a 33-gauge Hamilton sy-
ringe to the palatal interproximal gin-
giva between the first, second, and
third molars. The test group (N = 12) re-
ceived 10 mg/ml A. actinomycetemco-
mitans LPS, whereas the control group
(N = 6) received neutral 1· phosphate
buffered saline.
At 8 weeks, all animals were sacri-
ficed by carbon dioxide asphyxiation.
The maxillae were hemisected, and
posterior block sections were immersed
directly in 10% buffered formalin fixative
solution for 72 hours. All protocols were
approved by the University Committee
on the Use and Care of Animals at the
University of Michigan.
Micro-Computed Tomography
Non-demineralized rat maxillae were scanned in 70%
ethanol by a cone beam micro-computed tomogra-
phy (mCT) system.# Each scan was reconstructed
at a mesh size of 18 mm3, and three-dimensional dig-
itized images were generated for each specimen. By
using software,** it is possible to view the scans from
virtually any angle or cross-section. Therefore, a stan-
dardized orientation of the images was necessary
prior to measurement. First, the buccal and palatal
plates were made horizontal with the x-axis. Then the
x-plane was oriented so that it crossed through the
palatal roots. Parallelism of the molar cusps with
the x-axis was used for verification of alignment. A
threshold of 1,621 was set to distinguish between
mineralized and non-mineralized tissue in all scans.
Linear measurements were taken between the first
and second molars, from cemento-enamel junction
(CEJ) to alveolar bone crest (ABC), as described by
Park et al.22 Loss of bone volume was assessed using
three-dimensional isoform displays. After proper im-
age orientation, the region of interest (ROI) was des-
ignated. Width of the ROI was measured at the height
of contour of the molars. Height of the ROI was mea-
sured from molar cusp tips to root apices. The depth
was equal to the bucco-lingual size of the teeth plus
100 voxels (1.8 mm3). After establishing the
Figure 2.
A. actinomycetemcomitans LPS induced more inflammatory cell infiltrate into the area
adjacent to bone loss. Histologic appearance of representative control at low magnification
(A), and at high magnification (B), enlarged box area from A shows normal structure with
minimal inflammatory cells. A. actinomycetemcomitans LPS-injected rat periodontal tissues
at low magnification (C), and at high magnification (D), enlarged box area from C shows
significant inflammatory infiltrate is present.
¶ Charles River, Wilmington, MA.
# GE Healthcare BioSciences, Chalfont St. Giles, U.K.
** GEHC MicroView software,version Viz+ 2.0 build 0029, GE Healthcare,
Chalfont St. Giles, U.K.
Aa LPS Model for Aggressive Periodontitis Volume 78 • Number 3
552
threshold at 1,621, the bone volume fraction was cal-




Formalin-fixed specimens were decalcified in 10%
EDTA solution at 4C for 2 weeks. The EDTA solution
was changed three times per week. The maxillae were
embedded in paraffin and 5-mm sections were pre-
pared.
A few sections from each group were stained with
hematoxylin and eosin (H&E) for visualization of the
inflammatory infiltrate. Images were captured using
an inverted microscope†† and camera.‡‡
Immunohistochemical staining for IL-6 and -1b and
TNF-a was performed on tissue sections for both
groups. Deparaffinized tissue sections were placed
in antigen retrieval buffer§§ (in a pressure chamberii
for15 minutes, then removed andcooled to room tem-
perature. Primary antibodies of anti-rat IL-6, anti-rat
IL-1b, and anti-rat TNF-a monoclonal antibodies¶¶
were used (1:200 each antibody). Cytokine presence
was detected using reagent## and red
stain*** per manufacturer’s instructions.
Coverslips were seated on each slide
with histologic mounting medium.†††
Control sections were incubated with
preimmunoserum to assess background
staining. Images of the specimens were
captured using the inverted scope and
camera.
The digitized slide images were dis-
played on a computer screen for scoring
by two independent examiners. Exam-
iners were calibrated by comparing
images of a known intensity to a stan-
dardized score sheet containing repre-
sentative slides of one-, two-, three-, or
four-color intensity. All slides were dis-
played in random order and assigned a
score of 1, 2, 3, or 4; ‘‘1’’ represented
0% to 20% positive red stain, ‘‘2’’ repre-
sented 20% to 40% positive stain, ‘‘3’’
represented 40% to 60% positive stain,
and ‘‘4’’ represented >60% positive stain.
For detection of osteoclasts, tartrate-
resistant acid phosphatase (TRAP)
staining was performed for both groups
using a leukocyte acid phosphatase
kit.‡‡‡ Active osteoclasts were defined
as multinucleated TRAP-positive cells
in contact with the bone surface. Slides
from similar sagittal sections were used
to enumerate TRAP-positive cells.
Statistical Analysis
Differences among data were found by one-way anal-
ysis of variance (ANOVA) or post hoc analysis with
the Bonferroni test where indicated. P values <0.05
were considered significant.
RESULTS
Analysis of A. actinomycetemcomitans LPS
The A. actinomycetemcomitans LPS used in this study
contained no nucleic acid and minimal protein. The
absence of protein in A. actinomycetemcomitans
LPS preparations was confirmed by polyacrylamide
gel electrophoresis of extract samples and Coomassie
staining (Figs. 1A and 1B). The carbohydrate moie-
ties and lipid A fraction were visualized by silver
Figure 3.
mCT shows A. actinomycetemcomitans LPS induced significant linear bone loss.
A) Reformatted mCT isoform display from 8-week A. actinomycetemcomitans
LPS-injected rat maxillae exhibits dramatic palatal and interproximal bone loss. B) Linear
bone loss as measured from the CEJ to the ABC. Significant bone loss (*P <0.01) was
observed between control (N = 6) and A. actinomycetemcomitans LPS (Aa LPS)-injected
rats (N = 12).
†† Nikon TS100, Nikon, Melville, NY.
‡‡ Nikon CCD 5.1 megapixels, Nikon.
§§ Dako, Glostrup, Denmark.
ii Biocare Medical, Concord, CA.
¶¶ R&D Systems, Minneapolis, MN.
## Vectastain Elite ABC, Vector Labs, Burlingame, CA.
*** Nova Red, Vector Labs.
††† Permount, Fisher Scientific, Pittsburg, PA.
‡‡‡ Sigma, St. Louis, MO.
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nitrate–stained gels. Lipid A content also was ana-
lyzed by gas chromatography/mass spectrometry.
As shown in Figure 1C, the fatty acids found in the
preparation were identified by the mass spectral pat-
terns. The predominant major mass ion should be
1,827, which corresponds to a hexa-acylated diphos-
phorylated lipid A. Most of the LPS preparation con-
tains this species as observed previously.41 The
peak at 1,745 corresponds to a monophosphorylated
species (natural or created by the extraction proce-
dures), whereas peaks at 1,560 and 1,356 corre-
spond to the penta- and tetra-acylated species. The
amounts of this minor species are small compared
to the predominant m/z at 1,827.
A. actinomycetemcomitans LPS Induced
Inflammatory Infiltrate
The maxillae were fixed and embedded for histologic
staining by H&E. Sections from A. actinomycetemco-
mitans LPS-injected rats displayed significantly
greater inflammatory cell infiltrate (localized to the
connective tissue proximal to the junctional epithe-
lium and the surrounding alveolar crest) compared
to sections from vehicle-injected rats (Fig. 2). These
data illustrate that more inflammatory cells, predom-
inantly neutrophils and macrophages, were present in
the LPS-injected tissues, whereas relatively fewer in-
flammatory cells were present in the vehicle-injected
controls.
A. actinomycetemcomitans LPS Induced
Significant Alveolar Bone Loss
To evaluate the extent of alveolar bone loss and peri-
odontal destruction, mCT was used as described by
Park et al.22 Three-dimensional reformatted mCT im-
ages from 8-week specimens revealed a dramatic dif-
ference in the amount of bone destruction of the
maxillae (Fig. 3A, lower panel). In the rats that re-
ceived vehicle only, there was minimal bone loss
compared to non-injected rats (Fig. 3A, upper panel).
In the vehicle-injected controls, the alveolar crest was
in the coronal one-third of the roots, paralleling the
CEJs of the teeth. In contrast, specimens from the
A. actinomycetemcomitans LPS-injected group dis-
played a virtual obliteration of the palatal and inter-
proximal bone. The bony crest was located near the
molar apices, in a U-shaped configuration. The great-
est vertical destruction corresponded to the site of LPS
injection (the interproximal area between the molar
teeth).
Linear measurements from CEJs to ABCs revealed
mean bone losses of 0.405 mm in control animals and
1.04 mm in LPS-injected animals (Fig. 3). The overall
difference (0.634 mm) was statistically significant
(P <0.01) as assessed by one-way ANOVA.
For volumetric analysis, an ROI (highlighted area in
Fig. 4A) was used to determine the bone volume frac-
tion. By this unbiased approach, the bone volume
fraction was 0.42 for the vehicle group and 0.37 for
the LPS group (Fig. 4B). This difference was signifi-
cant (P <0.01) by one-way ANOVA.
A. actinomycetemcomitans LPS Induced
Inflammatory Cytokine Expression
To establish this periodontal model as an inflamma-
tory bone loss model, it was critical to characterize
inflammatory cytokine expression. Immunostaining
for selected key proinflammatory cytokines showed
marked differences between A. actinomycetemcomi-
tans LPS-treated and control samples (Fig. 5). Rela-
tive values were assigned using a graded scoring
system. The scores of ‘‘1’’ are from vehicle-injected
control animals (upper panels of Figs. 5A, 5C, and
5E), whereas a ‘‘4’’ score was given to the A. actino-
mycetemcomitans LPS-injected group (lower panels
of Figs. 5A, 5C, and 5E). A score of ‘‘0’’ was included
Figure 4.
A. actinomycetemcomitans LPS induced significant loss of proximal
bone volume. A) Reformatted mCT isoform display showing volumetric
ROI used for analysis. B) Analysis of mCT volumes were assessed
using software. Data are presented as percentage bone within ROI.
Significant bone loss (*P <0.001) was observed between control
(N = 6) and A. actinomycetemcomitans LPS (Aa LPS)-injected rats
(N = 12).
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as background staining from preim-
mune serum (data not shown). For IL-
6, the control group had a mean score
of 1.0 (range, 0 to 2), whereas the LPS
group had a mean score of 3.0 (range
2 to 4) (Fig. 5B). The difference was
similar for IL-1b (1.5 [range, 0 to 3]
and 2.75 [range, 1 to 4], respectively)
(Fig. 5D) and TNF-a (1.5 [range, 0 to
2] and 3 [range, 2 to 4], respectively)
(Fig. 5F). Scores of ‘‘4,’’ reflecting the
greatest prevalence of cytokine, were





Histologic examination and TRAP
staining were performed to quantify
osteoclastogenesis. Without A. actino-
mycetemcomitans LPS injection, few
osteoclasts were detected (Fig. 6). How-
ever, significantly more osteoclasts were
noted (P = 0.0023) after 8 weeks of A.
actinomycetemcomitans LPS exposure.
DISCUSSION
In the present study, we established a
new modelof aggressive periodontal dis-
ease in rats through localized injection
of highly purified A. actinomycetemco-
mitans LPS. At 8 weeks, evidence of
periodontal disease included increased
inflammatorycell infiltrate,enhanced in-
flammatory cytokine expression, and
stimulation of osteoclastogenesis man-
ifesting as significant alveolar bone loss.
We used mCT for the analysis of bone
area and volume. One of the distinct
advantages of this novel technique is
the use of the same specimens for histo-
logic examination following mCT scan-
ning. Moreover, the quality of the digital
data facilitates an easier assessment
than when using defleshed specimens.
Park et al.22 showed that three-dimen-
sional mCT imaging for linear and volu-
metric parameter assessment (height,
volume, mineral content, mineral den-
sity,andbonevolumefraction)washighly
reliable and reproducible with an intra-
class correlation coefficient of >0.99.
This suggested that three-dimensional
alveolar bone measurements might pro-
vide greater accuracy than conventional
Figure 5.
Pronounced expression of proinflammatory cytokines was observed in A.
actinomycetemcomitans LPS (Aa LPS)-injected animals. Histologic sections were
immunostained and detected using Nova Red reagent for IL-6 (A), IL-1b (C), or TNF-a
(E). B, D, and F) Immunohistochemical (IHC) scores from control animals and 8 weeks
post-LPS injections. Significant differences were observed for IL-6 (*P = 0.0104) and TNF-a
(*P = 0.0305) and approached significant differences between control and LPS-treated
groups for IL-1b (P = 0.0671). (Original magnification ·60.)
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two-dimensional methods. Future studies could use in
vivo mCT to document better progressive bone loss or
gain.
Consistent with the observation of severe bone loss,
there was a significant increase in the number of oste-
oclasts. Because rat molars undergo distal drift, there
is constant resorptive activity on the proximal bone;
therefore, osteoclasts were enumerated only on the
distal aspect of the interproximal bone.42,43 Analysis
following LPS injection showed that the number of
osteoclasts was relatively small (<10); however, this
number was not corrected per millimeter of bone sur-
face. The low number also may reflect the nature of
the experimental design; after an 8-week period of
LPS-induced bone loss, most of the osteoclastic bone
resorption already has occurred and the osteoclasts
haveundergone apoptosis. Nevertheless, the increase
in osteoclast count correlated well with the linear and
volumetric measurements of alveolar bone loss.
The impetus for the development of a new small an-
imal periodontitis model is the relative lack of such
models exhibiting robust amounts of inflammatory
bone loss with relevant periodontal pathogens. A ma-
jor limitation of the majority of Porphyromonas gingi-
valis infection models (versus LPS injection) is the
minimal amount of bone loss that occurs; mice and
rats display only fractions of a millimeter of bone loss
over the observation periods.44,45 Such minute bone
loss, typically <10% to 20% of the root length, hinders
evaluation of therapeutic treatment effects. Also, mod-
els described using E. coli endotoxin23 or ligature-
induced disease39,40 resulted in very
rapid and severe bone destruction (typi-
cally>50%bone loss)overa1- to2-week
period. These models represented acute
models of bone resorption, thereby
truncating the timeframe available for
observing therapeutic efficacy. The
amountof linearbone loss (;1mm)cre-
ated by A. actinomycetemcomitans LPS
over an 8-week period was more than
that created by E. coli LPS injected daily
over a 8-day period23 and slightly more
than E. coli LPS micropipetted daily into
rat gingival sulci over an 8-week obser-
vation period (0.65 mm difference).39
A. actinomycetemcomitans whole
bacteria injection models recently were
used in C57/Bl6 mice.26 Proinflamma-
tory cytokine expression, primarily T
helper 1–type TNF-a, was elevated sig-
nificantly in the first 30 days postinfec-
tion but it decreased in the last 30
days. In the present study, we observed
consistently high inflammatory cyto-
kine expression throughout a 60-day
period. This is similar to other oral pathogen-induced
bone loss models26,46 and consistent with the ability
of A. actinomycetemcomitans LPS to induce TNF-a
and IL-1b and -6 in vitro.47 Other in vitro data from
our research group showed that A. actinomycetemco-
mitans LPS can stimulate RANKL, IL-6, and MMP-13
expression as well as several periodontally relevant
cells, including periodontal ligament fibroblasts, oste-
oblasts, and macrophages.44,45,48
Female Sprague-Dawley rats were selected be-
cause of the preferred pharmacodynamics of a thera-
peutic used in a parallel-arm experiment. The amount
of inflammation present may have been affected by
female sex hormones, yet the exact nature and mech-
anism of such effects are largely unknown. In oopho-
rectomized Sprague-Dawley rats, daily injections of
estrogen and/or progesterone produced no difference
in infiltration of mononuclear cells or epithelial down-
growth compared to vehicle-injected sham-operated
controls.49 Recently, administration of 17b-estradiol
prevented ethanol-induced bone loss in female
Sprague-Dawley rats by blocking osteoblastic RANKL
mRNA induction and osteoclastogenesis.50 In our
study, all animals were of the same age and gender
and were assigned randomly, nullifying intergroup
differences. With sufficient sample size, intragroup
differences are negated as well.
CONCLUSIONS
We demonstrated that LPS endotoxin from the peri-
odontal pathogen A. actinomycetemcomitans initiated
Figure 6.
A. actinomycetemcomitans LPS delivery enhanced osteoclastogenesis. A) Histologic
sections were stained for TRAP. Arrows indicate TRAP-positive cells in A.
actinomycetemcomitans LPS (Aa LPS)-injected rats. B) Stained cells that were
TRAP-positive and had three or more nuclei were enumerated. LPS-injected animals
(N = 12) exhibited significantly more TRAP-positive cells than control animals
(N = 6; *P = 0.0023). (Scale bar = 1mm; original magnification ·60.)
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severe alveolar bone loss. Significant elevations in in-
flammatory cytokines and osteoclastogenesis were
consistent with the observed advanced bony destruc-
tion. The use of a well-established animal model of
periodontal disease, as demonstrated in this study,
will permit future evaluation of experimental thera-
peutics that target inflammatory alveolar bone loss.
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